MENU
+Compare
RGEN
Stock ticker: NASDAQ
AS OF
Apr 2 closing price
Price
$130.92
Change
+$2.42 (+1.88%)
Capitalization
10.26B

RGEN Repligen Corp Forecast, Technical & Fundamental Analysis

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies... Show more

Industry: #Biotechnology
RGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for RGEN with price predictions
Apr 01, 2025

RGEN in downward trend: price dove below 50-day moving average on March 07, 2025

RGEN moved below its 50-day moving average on March 07, 2025 date and that indicates a change from an upward trend to a downward trend. In of 36 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on March 25, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on RGEN as a result. In of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for RGEN turned negative on March 10, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at .

The 10-day moving average for RGEN crossed bearishly below the 50-day moving average on March 10, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RGEN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for RGEN entered a downward trend on April 01, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where RGEN's RSI Oscillator exited the oversold zone, of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RGEN advanced for three days, in of 347 cases, the price rose further within the following month. The odds of a continued upward trend are .

RGEN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. RGEN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.181) is normal, around the industry mean (23.715). P/E Ratio (247.520) is within average values for comparable stocks, (83.458). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (16.155) is also within normal values, averaging (41.612).

View a ticker or compare two or three
RGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

RGEN is expected to report earnings to fall 21.55% to 34 cents per share on April 30

Repligen Corp RGEN Stock Earnings Reports
Q1'25
Est.
$0.35
Q4'24
Beat
by $0.03
Q3'24
Beat
by $0.10
Q2'24
Est.
$0.33
Q1'24
Missed
by $0.02
The last earnings report on February 20 showed earnings per share of 43 cents, beating the estimate of 40 cents. With 624.32K shares outstanding, the current market capitalization sits at 10.26B.
A.I. Advisor
published General Information

General Information

a developer of biologic drugs

Industry MedicalSpecialties

Profile
Fundamentals
Details
Industry
Biotechnology
Address
41 Seyon Street
Phone
+1 781 250-0111
Employees
1783
Web
https://www.repligen.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SCHB21.760.15
+0.69%
Schwab US Broad Market ETF™
UNOV34.170.11
+0.32%
Innovator US Equity Ultra Buffer ETF Nov
PHB18.130.03
+0.17%
Invesco Fundamental Hi Yld® Corp Bd ETF
NUSA23.240.02
+0.11%
Nuveen ESG 1-5 Year US Aggt Bd ETF
ICOW31.58-0.03
-0.09%
Pacer Dev Mkts Intl Csh Cows 100 ETF

RGEN and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, RGEN has been loosely correlated with DHR. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if RGEN jumps, then DHR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGEN
1D Price
Change %
RGEN100%
+1.88%
DHR - RGEN
60%
Loosely correlated
+2.38%
A - RGEN
54%
Loosely correlated
+1.70%
BIO - RGEN
53%
Loosely correlated
+2.30%
TMO - RGEN
51%
Loosely correlated
+1.26%
BLFS - RGEN
50%
Loosely correlated
+4.16%
More